文献速递临床试验与 GCP流行病学与生物统计

阿拉伯子宫颈托预防双胎妊娠短宫颈早产评估(STOPPIT-2):开放标签随机试验与更新荟萃分析

Evaluation of the Arabin cervical pessary for prevention of preterm birth in women with a twin pregnancy and short cervix (STOPPIT-2): An open-label randomised trial and updated meta-analysis.
PubMed 文献 · PLoS Med · 2021-03-29

子宫颈托未显著降低 34 周前自然临产早产(18.4% 对 20.6%,aOR 0.87,95%CI 0.55-1.38,p=0.54)或新生儿复合结局(13.4% 对 15.0%,aOR 0.86,95%CI 0.54-1.36,p=0.50),更新荟萃分析亦未显示获益。

要点

  • 双胎妊娠宫颈长度≤35 mm 者,子宫颈托未显著降低 34 周前自然早产。
  • 子宫颈托未显著改善新生儿复合结局,两组围产儿死亡比例无显著差异。
  • 更新荟萃分析未显示子宫颈托降低短宫颈女性 34 周前早产风险。

核心结论

  • 结果使研究者拒绝「子宫颈托可降低主要结局风险 40%」的假设。
  • 不能排除更小的治疗效应。

研究设计与样本

  • 开放标签随机对照试验,在英国和欧洲 57 家医院产前门诊开展。
  • 503 名宫颈长度≤35 mm 女性随机分配至子宫颈托加标准护理组(n=250)或单纯标准护理组(n=253)。
  • 子宫颈托于孕 21 周前置入,孕 35 至 36 周或更早分娩前取出。

主要发现

  • 主要产科结局(34 周 0 天前自然临产并分娩)子宫颈托组 46/250(18.4%),标准护理组 52/253(20.6%),aOR 0.87(95%CI 0.55-1.38),p=0.54。
  • 主要新生儿复合结局子宫颈托组 67/500 例婴儿(13.4%),标准护理组 76/506 例(15.0%),aOR 0.86(95%CI 0.54-1.36),p=0.50。
  • 短宫颈(≤35 mm)预测 34 周前早产的阳性似然比为 2.14,阴性似然比为 0.83。
  • 子宫颈托组 4.4% 婴儿、标准治疗组 5.5% 婴儿在宫内或新生儿期死亡(p=0.53);两组均无女性死亡。

关键数值与推荐

  • 子宫颈托组主要产科结局 18.4%,标准护理组 20.6%,aOR 0.87(95%CI 0.55-1.38),p=0.54。
  • 子宫颈托组主要新生儿结局 13.4%,标准护理组 15.0%,aOR 0.86(95%CI 0.54-1.36),p=0.50。
  • 更新荟萃分析(4 项现有研究 313 名女性加 STOPPIT-2)显示子宫颈托未降低短宫颈女性 34 周前早产,风险比 0.74(95%CI 0.50-1.11),p=0.15。

临床怎么用

  • 双胎妊娠短宫颈女性不应常规使用阿拉伯子宫颈托以预防早产。
  • 临床决策需结合宫颈长度筛查结果及个体情况综合评估。

局限性

  • 研究把握度不足以排除小于 40% 的早产相关治疗效应。
  • 研究把握度不足以对亚组分析作出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm-labour-associated preterm birth is a common cause of perinatal mortality and morbidity in twin pregnancy. We aimed to test the hypothesis that the Arabin pessary would reduce preterm-labour-associated preterm birth by 40% or greater in women with a twin pregnancy and a short cervix. METHODS AND FINDINGS: We conducted an open-label randomised controlled trial in 57 hospital antenatal clinics in the UK and Europe. From 1 April 2015 to 14 February 2019, 2,228 women with a twin pregnancy underwent cervical length screening between 18 weeks 0 days and 20 weeks 6 days of gestation. In total, 503 women with cervical length ≤ 35 mm were randomly assigned to pessary in addition to standard care (n = 250, mean age 32.4 years, mean cervical length 29 mm, with pessary inserted in 230 women [92.0%]) or standard care alone (n = 253, mean age 32.7 years, mean cervical length 30 mm). The pessary was inserted before 21 completed weeks of gestation and removed at between 35 and 36 weeks or before birth if earlier. The primary obstetric outcome, spontaneous onset of labour and birth before 34 weeks 0 days of gestation, was present in 46/250 (18.4%) in the pessary group compared to 52/253 (20.6%) following standard care alone (adjusted odds ratio [aOR] 0.87 [95% CI 0.55-1.38], p = 0.54). The primary neonatal outcome-a composite of any of stillbirth, neonatal death, periventricular leukomalacia, early respiratory morbidity, intraventricular haemorrhage, necrotising enterocolitis, or proven sepsis, from birth to 28 days after the expected date of delivery-was present in 67/500 infants (13.4%) in the pessary group compared to 76/506 (15.0%) following standard care alone (aOR 0.86 [95% CI 0.54-1.36], p = 0.50). The positive and negative likelihood ratios of a short cervix (≤35 mm) to predict preterm birth before 34 weeks were 2.14 and 0.83, respectively. A meta-analysis of data from existing publications (4 studies, 313 women) and from STOPPIT-2 indicated that a cervical pessary does not reduce preterm birth before 34 weeks in women with a short cervix (risk ratio 0.74 [95% CI 0.50-1.11], p = 0.15). No women died in either arm of the study; 4.4% of babies in the Arabin pessary group and 5.5% of babies in the standard treatment group died in utero or in the neonatal period (p = 0.53). Study limitations include lack of power to exclude a smaller than 40% reduction in preterm labour associated preterm birth, and to be conclusive about subgroup analyses. CONCLUSIONS: These results led us to reject our hypothesis that the Arabin pessary would reduce the risk of the primary outcome by 40%. Smaller treatment effects cannot be ruled out. TRIAL REGISTRATION: ISRCTN Registry ISRCTN 02235181. ClinicalTrials.gov NCT02235181.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Norman JE, Norrie J, MacLennan G, et al. Evaluation of the Arabin cervical pessary for prevention of preterm birth in women with a twin pregnancy and short cervix (STOPPIT-2): An open-label randomised trial and updated meta-analysis. PLoS Med. 2021. PMID: 33780463. doi:10.1371/journal.pmed.1003506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。